M. Rengsberger

发表

Acute postoperative pain in 23 procedures of gynaecological surgery analysed in a prospective open registry study on risk factors and consequences for the patient

E. Schleußner, W. Meissner, I. Runnebaum, 2021, Scientific Reports.

An increase in cell number at completion of therapy may develop as an indicator of early relapse

T. Kroll, K. Pachmann, U. Pachmann, 2007, Journal of Cancer Research and Clinical Oncology.

Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells

K. Pachmann, O. Camara, A. Kavallaris, 2006, World journal of surgical oncology.

Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse.

K. Pachmann, U. Pachmann, M. Rengsberger, 2007, Breast.

p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer

I. Runnebaum, M. Dürst, H. Diebolder, 2013, Journal of Cancer Research and Clinical Oncology.

Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate

M. Gajda, H. Diebolder, I. Runnebaum, 2014, Journal of Cancer Research and Clinical Oncology.

Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements

A. Hochhaus, T. Ernst, T. Rachow, 2021, Journal of Cancer Research and Clinical Oncology.

Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome

E. Schill, M. Stauch, I. Runnebaum, 2013 .

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.

M. Untch, K. Pachmann, O. Camara, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

I. Runnebaum, M. Gajda, M. Dürst, 2021, Clinical epigenetics.

Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment

J. Huebner, A. Hochhaus, T. Ernst, 2021, Journal of Cancer Research and Clinical Oncology.

Extensive endometriosis surgery: rASRM and Enzian score independently relate to post-operative complication grade

T. Lehmann, H. Diebolder, I. Runnebaum, 2020, Archives of Gynecology and Obstetrics.

Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse.

K. Pachmann, U. Pachmann, M. Rengsberger, 2007, Breast.